Low serum melatonin levels are associated with erectile dysfunction

ArticleAçık Erişim

Özet

Objective: Melatonin is a hormone secreted from the pineal gland and has anti-oxidative and anti-inflammatory effects. Oxidative stress is considered as an important factor in the etiology of erectile dysfunction (ED), and in many experimental models, positive results have been obtained with melatonin treatment. This study aimed to measure serum melatonin levels in ED patients and to investigate the possible relationship between ED and melatonin levels. Materials and Methods: Sixty-two patients diagnosed with mild, moderate or severe ED according to the five-item International Erectile Function Index (IIEF-5) and 22 healthy individuals were included in the study. The serum melatonin levels, anthropometric data, and other biochemical and hormonal parameters of all the subjects were recorded. Detailed anamnesis was also obtained in terms of diabetes, hypertension, cardiovascular diseases, smoking status, and alcohol use. Results: The serum melatonin level was found 34.2±13.3 ng/dL in the mild ED group, 33.3±14.7 ng/dL in the moderate ED group, 34.8±17.2 ng/dL in the severe ED group, and 44.6±16.5 ng/dL in the control group. The serum melatonin levels were significantly lower in all ED groups compared to the control group (p=0.019). There was no significant difference in the serum melatonin levels between the three ED groups. Diabetes, hypertension, cardiovascular diseases, smoking and alcohol use were not significantly different between the ED groups (p>0.05). Conclusion: We consider that if our findings are supported by further studies with larger populations, the measurement of the serum melatonin level may have a future role in the diagnosis and treatment of ED. © 2018, Brazilian Society of Urology.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/14282Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorBozkurt, Aliseydi
dc.contributor.authorKarabakan, Mehmet
dc.contributor.authorAktas, Binhan Kagan
dc.contributor.authorGunay, Murat
dc.contributor.authorKeskin, Ercüment
dc.contributor.authorHirik, Erkan
dc.date.accessioned2026-10-18T20:29:05.034767083Z
dc.date.available2026-10-18T20:29:05.034767083Z
dc.date.issued2018
dc.description.abstractObjective: Melatonin is a hormone secreted from the pineal gland and has anti-oxidative and anti-inflammatory effects. Oxidative stress is considered as an important factor in the etiology of erectile dysfunction (ED), and in many experimental models, positive results have been obtained with melatonin treatment. This study aimed to measure serum melatonin levels in ED patients and to investigate the possible relationship between ED and melatonin levels. Materials and Methods: Sixty-two patients diagnosed with mild, moderate or severe ED according to the five-item International Erectile Function Index (IIEF-5) and 22 healthy individuals were included in the study. The serum melatonin levels, anthropometric data, and other biochemical and hormonal parameters of all the subjects were recorded. Detailed anamnesis was also obtained in terms of diabetes, hypertension, cardiovascular diseases, smoking status, and alcohol use. Results: The serum melatonin level was found 34.2±13.3 ng/dL in the mild ED group, 33.3±14.7 ng/dL in the moderate ED group, 34.8±17.2 ng/dL in the severe ED group, and 44.6±16.5 ng/dL in the control group. The serum melatonin levels were significantly lower in all ED groups compared to the control group (p=0.019). There was no significant difference in the serum melatonin levels between the three ED groups. Diabetes, hypertension, cardiovascular diseases, smoking and alcohol use were not significantly different between the ED groups (p>0.05). Conclusion: We consider that if our findings are supported by further studies with larger populations, the measurement of the serum melatonin level may have a future role in the diagnosis and treatment of ED. © 2018, Brazilian Society of Urology.
dc.identifier.doi10.1590/s1677-5538.ibju.2017.0663
dc.identifier.eissn1677-6119
dc.identifier.endpage793
dc.identifier.issn1677-5538
dc.identifier.issue4
dc.identifier.pmcidPMC6092660
dc.identifier.pmid29757573
dc.identifier.scopus2-s2.0-85050780660
dc.identifier.startpage785
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/14282
dc.identifier.volume44
dc.identifier.wosWOS:000437040700020
dc.language.isoen
dc.publisherBrazilian Society of Urology
dc.relation.ispartofInternational Braz J Urol
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectErectile dysfunction
dc.subjectEtiology [Subheading]
dc.subjectMelatonin
dc.subjectOxidative stress
dc.subjectAdult
dc.subjectBiomarkers
dc.subjectCardiovascular Diseases
dc.subjectCase-Control Studies
dc.subjectCholesterol
dc.subjectDiabetes Complications
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectHumans
dc.subjectHypertension
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRisk Factors
dc.subjectSeverity of Illness Index
dc.subjectSmoking
dc.subjectStatistics, Nonparametric
dc.subjectTriglycerides
dc.subjectbiological marker
dc.subjecttriacylglycerol
dc.subjectblood
dc.subjectcardiovascular disease
dc.subjectcase control study
dc.subjectcomplication
dc.subjectdeficiency
dc.subjectdiabetic complication
dc.subjectenzyme linked immunosorbent assay
dc.subjecthuman
dc.titleLow serum melatonin levels are associated with erectile dysfunction
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus16
rdl.citation.wos16
rdl.departmentDepartment of Urology, Erzincan University Mengucek Gazi Research and Training Hospital, Erzincan, Turkey. | Department of Clinical Biochemistry, Erzincan University Mengucek Gazi Research and Training Hospital, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)